EP2356109A4 - Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d autres maladies - Google Patents
Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d autres maladiesInfo
- Publication number
- EP2356109A4 EP2356109A4 EP09820030A EP09820030A EP2356109A4 EP 2356109 A4 EP2356109 A4 EP 2356109A4 EP 09820030 A EP09820030 A EP 09820030A EP 09820030 A EP09820030 A EP 09820030A EP 2356109 A4 EP2356109 A4 EP 2356109A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- diseases
- compositions
- methods
- alcohol use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007848 Alcoholism Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16187663.6A EP3135672B9 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
DK16187663.6T DK3135672T3 (da) | 2008-10-10 | 2009-10-12 | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme |
PL09820030T PL2356109T3 (pl) | 2008-10-10 | 2009-10-12 | Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób |
SI200931622A SI2356109T1 (sl) | 2008-10-10 | 2009-10-12 | Sestavki in postopki za zdravljenje motenj zaradi uživanja alkohola, bolečine in drugih bolezni |
PL16187663T PL3135672T3 (pl) | 2008-10-10 | 2009-10-12 | Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób |
HRP20170357TT HRP20170357T1 (hr) | 2008-10-10 | 2017-03-03 | Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti |
CY20201100404T CY1123625T1 (el) | 2008-10-10 | 2020-05-04 | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10467208P | 2008-10-10 | 2008-10-10 | |
PCT/US2009/060367 WO2010042925A2 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16187663.6A Division-Into EP3135672B9 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
EP16187663.6A Division EP3135672B9 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2356109A2 EP2356109A2 (fr) | 2011-08-17 |
EP2356109A4 true EP2356109A4 (fr) | 2012-05-30 |
EP2356109B1 EP2356109B1 (fr) | 2016-12-07 |
Family
ID=42101255
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09820030.6A Active EP2356109B1 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
EP16187663.6A Active EP3135672B9 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16187663.6A Active EP3135672B9 (fr) | 2008-10-10 | 2009-10-12 | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
Country Status (13)
Country | Link |
---|---|
US (1) | US8729081B2 (fr) |
EP (2) | EP2356109B1 (fr) |
CN (2) | CN106243100B (fr) |
CY (2) | CY1118665T1 (fr) |
DK (2) | DK3135672T3 (fr) |
ES (2) | ES2782376T3 (fr) |
HR (2) | HRP20170357T1 (fr) |
HU (2) | HUE033711T2 (fr) |
LT (2) | LT2356109T (fr) |
PL (2) | PL3135672T3 (fr) |
PT (2) | PT2356109T (fr) |
SI (2) | SI3135672T1 (fr) |
WO (1) | WO2010042925A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2356109T (lt) | 2008-10-10 | 2017-03-27 | Vm Discovery, Inc. | Kompozicijos ir būdai, skirti alkoholio vartojimo sutrikimų, skausmo ir kitų ligų gydymui |
WO2012051117A2 (fr) | 2010-10-11 | 2012-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Benzamides substitués et leurs utilisations |
KR20140048891A (ko) * | 2011-05-27 | 2014-04-24 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 치환된 2-벤질리덴-2H-벤조[b][1,4]티아진-3(4H)-온, 이의 유도체, 및 이의 치료적 용도 |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
MX2014012294A (es) * | 2012-04-12 | 2015-06-05 | Ruga Corp | Benzamidas sustituidas y sus usos. |
WO2014031792A2 (fr) | 2012-08-21 | 2014-02-27 | Sage Therapeutics | Procédés de traitement de l'épilepsie ou d'un état de mal épileptique |
CN104755083B (zh) * | 2012-10-11 | 2018-04-10 | 南方研究所 | 氨基烷基哌嗪的脲和酰胺衍生物及其用途 |
JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
EA034922B1 (ru) | 2013-03-15 | 2020-04-07 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US9676757B2 (en) * | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
WO2015192077A1 (fr) * | 2014-06-12 | 2015-12-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composés hétérocycliques et leurs méthodes d'utilisation |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
JP6838074B2 (ja) | 2016-03-08 | 2021-03-03 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
ES2696516B2 (es) * | 2017-07-12 | 2019-06-19 | Consejo Superior Investigacion | Compuestos derivados de piperidina como inhibidores de PDE8A |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CR20220559A (es) | 2020-05-04 | 2023-08-18 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008411A1 (fr) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras |
EP1394154A1 (fr) * | 2001-03-23 | 2004-03-03 | Takeda Chemical Industries, Ltd. | Derive heterocyclique a cinq membres d'acide alcanoique |
WO2005039549A1 (fr) * | 2003-10-27 | 2005-05-06 | Novartis Ag | Derives d'indolyle-pyrroledione pour traiter des troubles neurologiques et vasculaires lies a la generation et/ou a l'agregation de beta-amyloide |
EP1541564A1 (fr) * | 2002-09-10 | 2005-06-15 | Takeda Pharmaceutical Company Limited | Composes heterocycliques a cinq elements |
WO2005082367A1 (fr) * | 2004-02-18 | 2005-09-09 | Devgen Nv | Inhibiteurs de kinase |
WO2005097786A1 (fr) * | 2004-04-01 | 2005-10-20 | Sanofi-Aventis Deutschland Gmbh | Derives d'oxadiazolone utilises en tant qu'agonistes delta ppar |
WO2006103045A1 (fr) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation |
WO2007006546A1 (fr) * | 2005-07-11 | 2007-01-18 | Devgen N.V. | Derives d'amide utilises comme inhibiteurs des kinases |
WO2007107758A1 (fr) * | 2006-03-23 | 2007-09-27 | Prolysis Ltd | Agents antibactériens |
WO2008006043A2 (fr) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode |
EP1897872A1 (fr) * | 2005-05-25 | 2008-03-12 | Nippon Chemiphar Co., Ltd. | Activateur pour les recepteurs actives par les proliferateurs des peroxysomes |
WO2008038841A1 (fr) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Dérivé de thiadiazolone et utilisation de celui-ci |
EP1911738A1 (fr) * | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Composé de l acide phénoxyalkanoique |
WO2008117982A1 (fr) * | 2007-03-28 | 2008-10-02 | Crystal Genomics, Inc. | Dérivés d'acide carboxylique hétérocyclique et composition pharmaceutique les contenant pour inhiber l'accumulation des lipides |
WO2009042294A2 (fr) * | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
DE2711655A1 (de) | 1977-03-17 | 1978-09-21 | Basf Ag | Pyridinyl-aminoalkylaether |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
JP2002053566A (ja) * | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
US7595343B2 (en) * | 2001-09-14 | 2009-09-29 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
CA2471814C (fr) | 2001-12-27 | 2011-03-15 | Sumitomo Pharmaceuticals Co., Ltd. | Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active |
US20050038078A1 (en) * | 2003-08-11 | 2005-02-17 | Agouron Pharmaceuticals, Inc. | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use |
EP1981884B1 (fr) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Composés thiazoliques comme inhibiteurs de protéine kinase b |
WO2008053861A1 (fr) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Nouveau composé ayant un squelette 1,4-benzoxazin-3-one |
WO2008053863A1 (fr) * | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one |
US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
LT2356109T (lt) | 2008-10-10 | 2017-03-27 | Vm Discovery, Inc. | Kompozicijos ir būdai, skirti alkoholio vartojimo sutrikimų, skausmo ir kitų ligų gydymui |
JP6643807B2 (ja) | 2015-03-09 | 2020-02-12 | キヤノン株式会社 | 文書管理クライアント装置、文書管理方法 |
-
2009
- 2009-10-12 LT LTEP09820030.6T patent/LT2356109T/lt unknown
- 2009-10-12 SI SI200932055T patent/SI3135672T1/sl unknown
- 2009-10-12 EP EP09820030.6A patent/EP2356109B1/fr active Active
- 2009-10-12 PL PL16187663T patent/PL3135672T3/pl unknown
- 2009-10-12 PT PT98200306T patent/PT2356109T/pt unknown
- 2009-10-12 WO PCT/US2009/060367 patent/WO2010042925A2/fr active Application Filing
- 2009-10-12 DK DK16187663.6T patent/DK3135672T3/da active
- 2009-10-12 US US13/123,399 patent/US8729081B2/en active Active
- 2009-10-12 PT PT161876636T patent/PT3135672T/pt unknown
- 2009-10-12 HU HUE09820030A patent/HUE033711T2/en unknown
- 2009-10-12 SI SI200931622A patent/SI2356109T1/sl unknown
- 2009-10-12 ES ES16187663T patent/ES2782376T3/es active Active
- 2009-10-12 PL PL09820030T patent/PL2356109T3/pl unknown
- 2009-10-12 CN CN201610596312.2A patent/CN106243100B/zh active Active
- 2009-10-12 ES ES09820030.6T patent/ES2617873T3/es active Active
- 2009-10-12 CN CN200980141084.8A patent/CN102177153B/zh active Active
- 2009-10-12 LT LTEP16187663.6T patent/LT3135672T/lt unknown
- 2009-10-12 EP EP16187663.6A patent/EP3135672B9/fr active Active
- 2009-10-12 HU HUE16187663A patent/HUE050319T2/hu unknown
- 2009-10-12 DK DK09820030.6T patent/DK2356109T3/en active
-
2017
- 2017-02-22 CY CY20171100243T patent/CY1118665T1/el unknown
- 2017-03-03 HR HRP20170357TT patent/HRP20170357T1/hr unknown
-
2020
- 2020-04-04 HR HRP20200552TT patent/HRP20200552T1/hr unknown
- 2020-05-04 CY CY20201100404T patent/CY1123625T1/el unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1394154A1 (fr) * | 2001-03-23 | 2004-03-03 | Takeda Chemical Industries, Ltd. | Derive heterocyclique a cinq membres d'acide alcanoique |
WO2003008411A1 (fr) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras |
EP1541564A1 (fr) * | 2002-09-10 | 2005-06-15 | Takeda Pharmaceutical Company Limited | Composes heterocycliques a cinq elements |
WO2005039549A1 (fr) * | 2003-10-27 | 2005-05-06 | Novartis Ag | Derives d'indolyle-pyrroledione pour traiter des troubles neurologiques et vasculaires lies a la generation et/ou a l'agregation de beta-amyloide |
WO2005082367A1 (fr) * | 2004-02-18 | 2005-09-09 | Devgen Nv | Inhibiteurs de kinase |
WO2005097786A1 (fr) * | 2004-04-01 | 2005-10-20 | Sanofi-Aventis Deutschland Gmbh | Derives d'oxadiazolone utilises en tant qu'agonistes delta ppar |
WO2006103045A1 (fr) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation |
EP1897872A1 (fr) * | 2005-05-25 | 2008-03-12 | Nippon Chemiphar Co., Ltd. | Activateur pour les recepteurs actives par les proliferateurs des peroxysomes |
WO2007006546A1 (fr) * | 2005-07-11 | 2007-01-18 | Devgen N.V. | Derives d'amide utilises comme inhibiteurs des kinases |
EP1911738A1 (fr) * | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Composé de l acide phénoxyalkanoique |
WO2007107758A1 (fr) * | 2006-03-23 | 2007-09-27 | Prolysis Ltd | Agents antibactériens |
WO2008006043A2 (fr) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode |
WO2008038841A1 (fr) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Dérivé de thiadiazolone et utilisation de celui-ci |
WO2008117982A1 (fr) * | 2007-03-28 | 2008-10-02 | Crystal Genomics, Inc. | Dérivés d'acide carboxylique hétérocyclique et composition pharmaceutique les contenant pour inhiber l'accumulation des lipides |
WO2009042294A2 (fr) * | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations |
Non-Patent Citations (5)
Title |
---|
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 August 2006 (2006-08-10), XP002672241, Database accession no. 902619-02-7 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 October 2007 (2007-10-12), XP002672245, Database accession no. 950436-85-8 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 August 2006 (2006-08-16), XP002672242, Database accession no. 901716-44-7 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 September 2008 (2008-09-19), XP002672244, Database accession no. 1050553-20-2 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 August 2008 (2008-08-22), XP002672243, Database accession no. 1016358-28-3 * |
Also Published As
Publication number | Publication date |
---|---|
EP2356109B1 (fr) | 2016-12-07 |
EP2356109A2 (fr) | 2011-08-17 |
ES2617873T3 (es) | 2017-06-20 |
PT2356109T (pt) | 2017-03-10 |
HRP20200552T1 (hr) | 2020-07-10 |
DK3135672T3 (da) | 2020-05-04 |
PT3135672T (pt) | 2020-04-02 |
WO2010042925A2 (fr) | 2010-04-15 |
HUE033711T2 (en) | 2017-12-28 |
US20110301149A1 (en) | 2011-12-08 |
SI2356109T1 (sl) | 2017-04-26 |
WO2010042925A3 (fr) | 2010-07-29 |
EP3135672B9 (fr) | 2020-05-20 |
LT3135672T (lt) | 2020-05-25 |
EP3135672B1 (fr) | 2020-02-19 |
HRP20170357T1 (hr) | 2017-05-05 |
PL2356109T3 (pl) | 2017-07-31 |
CY1123625T1 (el) | 2022-03-24 |
CN106243100B (zh) | 2019-04-09 |
CN102177153B (zh) | 2016-09-21 |
CY1118665T1 (el) | 2017-07-12 |
CN102177153A (zh) | 2011-09-07 |
EP3135672A1 (fr) | 2017-03-01 |
ES2782376T3 (es) | 2020-09-14 |
US8729081B2 (en) | 2014-05-20 |
SI3135672T1 (sl) | 2020-07-31 |
PL3135672T3 (pl) | 2020-11-16 |
LT2356109T (lt) | 2017-03-27 |
CN106243100A (zh) | 2016-12-21 |
DK2356109T3 (en) | 2017-03-13 |
HUE050319T2 (hu) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2356109A4 (fr) | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d autres maladies | |
EP2176283A4 (fr) | Methodes et compositions de traitement des maladies cerebrales | |
EP2260109A4 (fr) | Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate | |
HK1158172A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
IL202424A (en) | Telomerase activator compounds for use in the treatment of disorders and related conditions | |
PL2349231T3 (pl) | Kompozycje i metody leczenia chorób kopyta | |
HK1245679A1 (zh) | 用於治療皮膚疾病和病症的方法和組合物 | |
IL211313A0 (en) | Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies | |
ZA201100459B (en) | Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders | |
HK1149545A1 (en) | Compositions and methods for treating ophthalmic diseases | |
GB0915259D0 (en) | Sulphur-linked compounds for treating ophthalmic diseases and disorders | |
EP2274411A4 (fr) | Compositions de xanthohumol et procédés de traitement des maladies ou des affections cutanées | |
EP2217238A4 (fr) | Procédés et compositions pour le traitement de maladies protéinuriques | |
HK1232162A1 (zh) | 治療疼痛症狀及其它失調的化合物 | |
IL213703A0 (en) | Compounds and methods for the treatment of pain and other diseases | |
GB0822158D0 (en) | Method,composition and device for the treatment of enzymes and saccharides disorders | |
EP2515925A4 (fr) | Compositions et méthodes pour prévenir et traiter les maladies et les troubles de santé induits par l'environnement | |
GB0822486D0 (en) | Compounds for use in the treatment of pain | |
EP2654434A4 (fr) | Procédés pour le traitement de maladies, troubles et lésions dentaires | |
HK1165280A1 (zh) | 芐達明在治療 依賴性疾病中的用途 | |
PT2278962E (pt) | Métodos para o tratamento de desordens dermatológicas | |
EP2432322A4 (fr) | Compositions et méthodes de traitement optimales d'affections et de douleurs bucco-dentaires | |
GB0814043D0 (en) | The treatment of skin disorders | |
GB0716834D0 (en) | New formulation for treatment of skin disorders | |
GB0616122D0 (en) | Formulation for treatment of skin disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110510 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WU, JAY JIE-QIANG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VM DISCOVERY, INC. |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 279/14 20060101ALI20120416BHEP Ipc: C07D 401/02 20060101ALI20120416BHEP Ipc: A61K 31/4162 20060101ALI20120416BHEP Ipc: C07D 241/40 20060101ALI20120416BHEP Ipc: C07D 487/04 20060101ALI20120416BHEP Ipc: C07D 265/36 20060101ALI20120416BHEP Ipc: A61P 35/00 20060101ALI20120416BHEP Ipc: C07D 401/14 20060101AFI20120416BHEP Ipc: C07D 498/04 20060101ALI20120416BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120426 |
|
17Q | First examination report despatched |
Effective date: 20130517 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160219 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160707 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 851583 Country of ref document: AT Kind code of ref document: T Effective date: 20161215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009042972 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161207 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20170357 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2356109 Country of ref document: PT Date of ref document: 20170310 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20170303 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20170309 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20161207 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E013344 Country of ref document: EE Effective date: 20170302 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20170357 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2617873 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170620 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20170400639 Country of ref document: GR Effective date: 20170804 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009042972 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
26N | No opposition filed |
Effective date: 20170908 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E033711 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170357 Country of ref document: HR Payment date: 20190920 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 851583 Country of ref document: AT Kind code of ref document: T Effective date: 20161207 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170357 Country of ref document: HR Payment date: 20200923 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170357 Country of ref document: HR Payment date: 20210923 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170357 Country of ref document: HR Payment date: 20220921 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170357 Country of ref document: HR Payment date: 20230919 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230928 Year of fee payment: 15 Ref country code: SM Payment date: 20230926 Year of fee payment: 15 Ref country code: RO Payment date: 20230922 Year of fee payment: 15 Ref country code: EE Payment date: 20230920 Year of fee payment: 15 Ref country code: CZ Payment date: 20230925 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230919 Year of fee payment: 15 Ref country code: PT Payment date: 20230926 Year of fee payment: 15 Ref country code: PL Payment date: 20230926 Year of fee payment: 15 Ref country code: NL Payment date: 20231026 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20230919 Year of fee payment: 15 Ref country code: LV Payment date: 20230919 Year of fee payment: 15 Ref country code: LU Payment date: 20231027 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20231027 Year of fee payment: 15 Ref country code: GB Payment date: 20231027 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231102 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20230920 Year of fee payment: 15 Ref country code: SE Payment date: 20231027 Year of fee payment: 15 Ref country code: NO Payment date: 20231027 Year of fee payment: 15 Ref country code: IT Payment date: 20231023 Year of fee payment: 15 Ref country code: IE Payment date: 20231027 Year of fee payment: 15 Ref country code: HU Payment date: 20230927 Year of fee payment: 15 Ref country code: FR Payment date: 20231025 Year of fee payment: 15 Ref country code: FI Payment date: 20231025 Year of fee payment: 15 Ref country code: DK Payment date: 20231027 Year of fee payment: 15 Ref country code: DE Payment date: 20231027 Year of fee payment: 15 Ref country code: CY Payment date: 20230920 Year of fee payment: 15 Ref country code: CH Payment date: 20231102 Year of fee payment: 15 Ref country code: BG Payment date: 20231018 Year of fee payment: 15 Ref country code: AT Payment date: 20230920 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231027 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20230919 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20240923 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20240918 Year of fee payment: 16 Ref country code: HR Payment date: 20240919 Year of fee payment: 16 Ref country code: MC Payment date: 20240920 Year of fee payment: 16 |